Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Vernon, John A.
Golec, Joseph H.
and
Stevens, J. Stedman
2010.
Comparative Effectiveness Regulations and Pharmaceutical Innovation.
PharmacoEconomics,
Vol. 28,
Issue. 10,
p.
877.
Golec, Joseph
and
Vernon, John A.
2010.
Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms.
PharmacoEconomics,
Vol. 28,
Issue. 8,
p.
615.
Smith, Brian D.
2011.
ResearchWatch.
Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing,
Vol. 11,
Issue. 1,
p.
93.
Vernon, John A
and
Golec, Joseph H
2011.
Correctly measuring drug development risk: a public policy imperative.
Expert Review of Pharmacoeconomics & Outcomes Research,
Vol. 11,
Issue. 1,
p.
1.
Cook, Joseph P.
Golec, Joseph H.
Vernon, John A.
and
Pink, George H.
2011.
Real Option Value and Path Dependence in Oncology Innovation.
International Journal of the Economics of Business,
Vol. 18,
Issue. 2,
p.
225.
Giaccotto, Carmelo
Golec, Joseph
and
Vernon, John
2011.
New estimates of the cost of capital for pharmaceutical firms.
Journal of Corporate Finance,
Vol. 17,
Issue. 3,
p.
526.
Lioui, Abraham
and
Sharma, Zenu
2012.
Environmental corporate social responsibility and financial performance: Disentangling direct and indirect effects.
Ecological Economics,
Vol. 78,
Issue. ,
p.
100.
Levaggi, Rosella
Moretto, Michele
and
Pertile, Paolo
2013.
The Dynamics of Pharmaceutical Regulation and R&D Investments.
SSRN Electronic Journal,
Blume-Kohout, Margaret E.
and
Sood, Neeraj
2013.
Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development.
Journal of Public Economics,
Vol. 97,
Issue. ,
p.
327.
Seng-Ho Jeon
Choi, Joung Hwa
and
김종오
2014.
Relationship between R&D Efforts and Firm Value in the Pharmaceutical Industry.
The Journal of International Trade & Commerce,
Vol. 10,
Issue. 5,
p.
67.
Koijen, Ralph S. J.
Philipson, Tomas
and
Uhlig, Harald
2014.
Financial Health Economics.
SSRN Electronic Journal,
Pekarsky, Brita A. K.
2015.
The New Drug Reimbursement Game.
p.
37.
Wakutsu, Naohiko
and
Nakamura, Hiroshi
2015.
New NHI Drug-pricing System in Japan: Incentives for R&D and Budget Neutrality.
International Journal of Economic Policy Studies,
Vol. 10,
Issue. 1,
p.
1.
Wakutsu, Naohiko
and
Nakamura, Hiroshi
2015.
Analyzing the Benefits from New NHI Drug Pricing System in Japan: Factor Decomposition and Simulation.
Iryo To Shakai,
Vol. 25,
Issue. 2,
p.
205.
Shibata, Shoyo
Uemura, Ryotaro
and
Suzuki, Takeshi
2016.
Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market: An Analysis by Therapeutic Area.
Therapeutic Innovation & Regulatory Science,
Vol. 50,
Issue. 1,
p.
49.
Jobjörnsson, Sebastian
Forster, Martin
Pertile, Paolo
and
Burman, Carl-Fredrik
2016.
Late-stage pharmaceutical R&D and pricing policies under two-stage regulation.
Journal of Health Economics,
Vol. 50,
Issue. ,
p.
298.
Shibata, Shoyo
Uemura, Ryotaro
and
Suzuki, Takeshi
2016.
Evaluating the Effectiveness of Repricing for Market Expansion in the Japanese Drug Pricing System.
Therapeutic Innovation & Regulatory Science,
Vol. 50,
Issue. 6,
p.
751.
Maniadakis, N.
Kourlaba, G.
Shen, J.
and
Holtorf, A.
2017.
Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.
BMC Health Services Research,
Vol. 17,
Issue. 1,
Chan, Konan
Lin, Yueh-Hsiang
and
Wang, Yanzhi
2017.
Limits-to-arbitrage, investment frictions, and innovation anomalies.
Pacific-Basin Finance Journal,
Vol. 43,
Issue. ,
p.
1.
LEVAGGI, ROSELLA
MORETTO, MICHELE
and
PERTILE, PAOLO
2017.
The Dynamics of Pharmaceutical Regulation and R&D Investments.
Journal of Public Economic Theory,
Vol. 19,
Issue. 1,
p.
121.